Free Biopharma Daily Stock Updates - 03/16/21

$XBI $145.89 -2% 📉

Want to access our searchable database of over 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$MRNA +9% Doses first patient in ph 2/3 study of covid vaccine in pediatric population. source


Pipeline Updates

$AVXL +9% Ph 3 results of ANAVEX 2-73 in neurodegenerative disorders published in journal of Neuropharmacology. source


$SPPI -4% FDA scheduled a pre-approval inspection of their ROLONTIS manufacturing facility in South Korea in May 2021. In Oct 2020 FDA deferred decision on BLA because inspection could not be conducted due to covid-19 travel restrictions. source


$FGEN -2% Initiate LELANTOS-2, 2nd ph 3 study of pamrevlumab for Duchenne muscular dystrophy. source


$GBT -4% In-licenses 2 early-stage sickle cell disease assets from Sanofi. Mechanism differentiated from Vox support the companies strategy to address SCD. source


$KALA +4% Cigna adds EYSUVIUS 0.25% as a preferred brand on it's commercial formulary. source


$KDNY -7% First patient dosed in ph 3 study of atrasentan for IGA nephropathy. source

0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE